Journal of Family & Community Medicine
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contact us Login 
 

Users Online: 105 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

 

    Article Cited by others

ORIGINAL ARTICLE

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection

Ismail Mona H

Year : 2013| Volume: 20| Issue : 1 | Page no: 35-40

   This article has been cited by
 
1 Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
Mawuena Binka,Naveed Z. Janjua,Jason Grebely,Chris Estes,Dena Schanzer,Jisoo A. Kwon,Naglaa H. Shoukry,Jeffrey C. Kwong,Homie Razavi,Jordan J. Feld,Mel Krajden
JAMA Network Open. 2020; 3(5): e204192
[Pubmed]  [Google Scholar] [DOI]
2 Vedroprevir in the management of hepatitis C virus infection
Ameer Abutaleb,Shyamasundaran Kottilil
Expert Opinion on Investigational Drugs. 2017; 26(12): 1399
[Pubmed]  [Google Scholar] [DOI]
3 Pathology Predictors of Response to Combined Therapy of Chronic HCV Patients; Is it Applicable in the DAA Era?
Samar Kamal Darweesh
Gastroenterology & Hepatology: Open Access. 2016; 5(8)
[Pubmed]  [Google Scholar] [DOI]
4 Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients
Gouda K. Helal,Magdy A. Gad,Mohamed F. Abd-Ellah,Elsayed M. Mahgoup
European Journal of Gastroenterology & Hepatology. 2016; 28(5): 553
[Pubmed]  [Google Scholar] [DOI]
5 New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir
Sean M. McConachie,Sheila M. Wilhelm,Pramodini B. Kale-Pradhan
Expert Review of Clinical Pharmacology. 2016; 9(2): 287
[Pubmed]  [Google Scholar] [DOI]
6 Genetic variant ofIL28Brs12979860, as predictive marker of interferon-based therapy in Pakistani population
Muhammad Imran,Sobia Manzoor,Sikandar Azam,Saleha Resham
APMIS. 2015; 123(4): 342
[Pubmed]  [Google Scholar] [DOI]
7 Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian Patients
Ekram W. Abd El-Wahab,Ashraf Mikheal,Fathallah Sidkey,Hanan Z. Shatat
Journal of Medical Virology. 2015; 87(3): 428
[Pubmed]  [Google Scholar] [DOI]
8 High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study
Leila Mehrnoush,Seyed-Moayed Alavian,Heidar Sharafi,Bita Behnava,Shima Salimi,Maryam Keshvari
Pediatric Hematology and Oncology. 2015; 32(6): 399
[Pubmed]  [Google Scholar] [DOI]
9 Asunaprevir (BMS-650032) for the treatment of hepatitis C virus
Nobuhisa Akamatsu,Yasuhiko Sugawara,Norihiro Kokudo
Expert Review of Anti-infective Therapy. 2015; 13(11): 1307
[Pubmed]  [Google Scholar] [DOI]
10 Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection
Ivan Gentile,Antonio Riccardo Buonomo,Guglielmo Borgia
Expert Review of Anti-infective Therapy. 2014; 12(9): 1033
[Pubmed]  [Google Scholar] [DOI]
11 Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection
Ivan Gentile,Antonio Riccardo Buonomo,Federico Borgia,Giuseppe Castaldo,Guglielmo Borgia
Expert Opinion on Investigational Drugs. 2014; 23(4): 561
[Pubmed]  [Google Scholar] [DOI]
12 Asunaprevir-containing regimens for the treatment of hepatitis C virus infection
Sheng-Shun Yang,Jia-Horng Kao
Expert Review of Gastroenterology & Hepatology. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
13 Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
Ivan Gentile,Nicola Coppola,Antonio Riccardo Buonomo,Emanuela Zappulo,Guglielmo Borgia
Expert Opinion on Investigational Drugs. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
14 Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Ivan Gentile,Antonio Riccardo Buonomo,Emanuela Zappulo,Guglielmo Borgia
Expert Review of Anti-infective Therapy. 2014; 12(7): 763
[Pubmed]  [Google Scholar] [DOI]
15 Discontinued drugs in 2012 2013: hepatitis C virus infection
Ivan Gentile,Antonio Riccardo Buonomo,Emanuela Zappulo,Guglielmo Borgia
Expert Opinion on Investigational Drugs. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
16 MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection
Ivan Gentile,Antonio Riccardo Buonomo,Federico Borgia,Emanuela Zappulo,Giuseppe Castaldo,Guglielmo Borgia
Expert Opinion on Investigational Drugs. 2014; 23(5): 719
[Pubmed]  [Google Scholar] [DOI]
17 GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection
Ivan Gentile,Antonio Riccardo Buonomo,Emanuela Zappulo,Nicola Coppola,Guglielmo Borgia
Expert Review of Anti-infective Therapy. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article
Advertise | Sitemap | What's New | Feedback | Disclaimer
Journal of Family and Community Medicine | Published by Wolters Kluwer - Medknow
Online since 05th September, 2010